this post was submitted on 20 Mar 2025
17 points (90.5% liked)

Public Health

993 readers
41 users here now

For issues concerning:


🩺 This community has a broader scope so please feel free to discuss. When it may not be clear, leave a comment talking about why something is important.



Related Communities

See the pinned post in the Medical Community Hub for links and descriptions. link (!medicine@lemmy.world)


Rules

Given the inherent intersection that these topics have with politics, we encourage thoughtful discussions while also adhering to the mander.xyz instance guidelines.

Try to focus on the scientific aspects and refrain from making overly partisan or inflammatory content

Our aim is to foster a respectful environment where we can delve into the scientific foundations of these topics. Thank you!

founded 2 years ago
MODERATORS
 

We might be on the precipice of a pivotal moment in Alzheimer’s disease research. In clinical trial data released this week, scientists have presented early evidence that it’s possible to delay symptoms in people genetically fated to develop Alzheimer’s at a young age.

Researchers at the Washington University School of Medicine led the study, which aimed to test whether an experimental anti-amyloid drug called gantenerumab could help people with an inherited form of Alzheimer’s. In a subset of patients treated the longest, the drug appeared to reduce their risk of developing symptoms as expected, by 50%. The findings will require a follow-up, but outside experts are cautiously optimistic about what this could mean for the future of treating Alzheimer’s.

no comments (yet)
sorted by: hot top controversial new old
there doesn't seem to be anything here